【摘要】 目的:比较达比加群酯与华法林用于非瓣膜性心房颤动(NVAF)患者抗凝的有效性和安全性。方法:回顾性分析360例NVAF患者资料,按用药方案的不同分为对照组(180例)和观察组(180例)。对照组患者给予华法林钠片,起始剂量2.5 mg,口服,每日1次,根据国际标准化比值(INR)调整剂量。观察组患者给予达比加群酯胶囊150 mg,每日2次,温水送服,餐时或餐后服用。观察两组患者治疗前与治疗1、3个月后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)水平、INR及不良反应发生情况。结果:两组患者治疗前后ALT、AST水平比较,差异均无统计学意义(P>0.05)。治疗前,两组患者INR比较,差异无统计学意义(P>0.05)。治疗1、3个月后,对照组患者INR均显著高于同组治疗前,差异有统计学意义(P<0.05);观察组患者治疗前后比较,差异均无统计学意义(P>0.05),但两组患者INR值均在正常范围内。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达比加群酯治疗NVAF患者的抗凝有效性显著优于华法林,且两药的安全性相当。更多还原

【Abstract】 OBJECTIVE:To compare anticoagulant efficacy and safety of dabigatran etexilate and warfarin in the treatment of non-valvular atrial fibrillation(NVAF). METHODS:In retrospective analysis,360 NVAF patients were divided into control group(180 cases)and observation group(180 cases)according to therapy plan. Control group was given Warfarin sodium tablet with initial dose of 2.5 mg orally,once a day,adjusted dosage according to INR. Observation group was given Dabigatran etexilate capsule 150 mg with warm water,twice a day,during or after meal. The levels of ALT,AST and INR,the occurrence of ADR were observed in 2 groups before treatment and 1,3 month after treatment. RESULTS:There was no statistical significance in the levels of ALT or AST between 2 groups before and after treatment(P>0.05). Before treatment,there was no statistical significance in INR between 2 groups(P>0.05),1,3 months after treatment,INR in control group was significantly higher than before treatment,with statistical significance(P<0.05);there was no statistical significance in the INR of observation group before and after treatment(P>0.05);but INR of 2 groups ranged were in normal range. There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Anticoagnlant efficacy of dabigatran etexilate is significantly better than warfarin for NVAF. Both have similar safety.更多还原